Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Zulujora Tojall
Country: Bahamas
Language: English (Spanish)
Genre: Photos
Published (Last): 4 November 2006
Pages: 471
PDF File Size: 14.89 Mb
ePub File Size: 18.74 Mb
ISBN: 311-1-88650-918-4
Downloads: 64373
Price: Free* [*Free Regsitration Required]
Uploader: Kagagami

Documents Flashcards Grammar checker. RT PCR para t 11; Crioglobulinas si HVC positivo.

LEZM – Linfoma Esplénico de la Zona Marginal

CD 5- CD 10Otros: Hay algunos casos con t 11;14 pero el punto de ruptura es diferente al linfoma del manto. Sobre todo con linfomas de bajo grado nodales primarios si afectan al bazo. CD 10 y bcl-6, la t 14; Puede estar infiltrada la medula pero con buena reserva medular.

Watch and wait con vigilancia cada meses: Valorar profilaxis con fluconazol mg po. No respuesta o enfermedad progresiva: Pacientes con F o FC con o sin Rituximab: Si neutropenia G-CSF o profilaxis con ciprofloxacino. Splenic marginal zone lymphoma with and without villous lymphocytes.

Curr Treat Options Oncol. Epub Feb The Integruppo Italiano Linfomi IIL carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in patients. Using these 3 variables, we grouped patients into 3 prognostic categories: The causespecific mortality rate x person-years was 20 for the low-risk group, 47 for the intermediate-risk group, and for the high-risk group.

Orphanet: Linfoma esplenico de la zona marginal

In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol Oct;99 1: All four had relapsed after, or failed to respond to, recommended first-line therapies.

In each case fludarabine resulted in a complete clinico-haematological response with minimal toxicity, which, in the two patients with long-term follow-up, proved durable. Fludarabine is effective in the treatment of SLVL and should be margnial as both a first-line therapeutic option as well as salvage therapy in this condition.

Dramatic efficacy esplemico fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Splenectomy is primarily recommended for treating this disease, and splenic irradiation or alkylating agents may be effective; however, frequent recurrence is observed after these therapies.

Although the effects of splenic irradiation and combination chemotherapy were both unsatisfactory and transient, complete remission lasting for more than 15 months was achieved after two courses of treatment with low-dose fludarabine 15 mg m -2 daily for 3 d.


The present case indicates that treatment with fludarabine is effective for SLVL and recommended as the first-line therapy for elderly patients and those with an aggressive form of the disease. However, a few patients relapse and the second-line treatment remains questionable. The median 10 Grupo Asturiano de Linfomas Noviembre duration between diagnosis and treatment was 17 months range, Two patients were previously untreated.


All patients were assessable: One out of the three partial responders have a persistent response. The treatment was well tolerated. FDR appears to be an efficient therapy with a favorable toxicity profile for patients in relapse after splenectomy or resistant to CLB. Furthermore it could constitute an alternative to splenectomy in older patients. A longer follow-up and the study of a larger group of patients are warranted to confirm our findings.

Low dose 2CdA schedule activity in splenic marginal zone lymphomas. SMZL is an indolent lymphoma usually treated by splenectomy. A subset of patients is characterized by a more aggressive clinical course and poor prognosis. Treatment of these cases and second-line therapy for relapsed patients have not been yet identified. Interestingly, in addition to a relevant percentage of hematological remission, some patients also experienced a molecular remission.

We conclude that this treatment is safe and well tolerated and is able to induce a substantial number of responses. Esplennico results suggest that this schedule is well tolerated and could be an useful alternative to splenectomy. Deoxycoformycin pentostatin in the treatment of splenic marginal zone lymphoma SMZL with or without villous lymphocytes. Signs and symptoms, mostly related to ypersplenism, are successfully managed by splenectomy.

However, the therapy ofpatients who are not fit for a surgical procedure or who relapse after plenectomy, is still an unsettled issue. In relapsed patients, the median interval between diagnosis and treatment was 6 month range: Two out three patients, who received pentostatin as first line therapy, ttained a complete response CR.

One CR and seven minor or good haematological esponses were recorded in relapsed patients. Treatment toxicity, mostly hematological, proved manageable. With a median follow-up of 35 month the median overall survival OS is 40 month and the median progression free survival PFS marginaal 18 month.

Our data show that pentostatin administered every other week has a good degree of activity in the treatment of SMZL and suggest that this schedule could be considered a possible therapeutic option for patients who are not fit for splenectomy or have relapsed. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.

The objective of this retrospective study was marginla compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or 11 Grupo Asturiano de Linfomas Noviembre chemotherapy alone. The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May and October The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia.

SMZL was confirmed in 70 patients. The median age was 64 years. The median number of CD20 molecules per cell was 69 x 10 3. Forty-three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients. Ten additional patients underwent splenectomy, and 17 patients were in the observation group. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. In univariate analysis, younger age and rituximab-based therapy were predictive of longer FFS.


Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. These results may be associated with high levels of cellular CD20 antigen sites.

Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Splenectomy has traditionally been considered as a standard first line treatment for splenic esplenicco zone lymphoma SMZL conferring a survival advantage over chemotherapy.

However it carries significant eplenico, especially in elderly patients. The purpose of this retrospective study was to report our experience on the efficacy of Rituximab as first line treatment in 16 consecutive SMZL patients, diagnosed in our department.

The diagnosis was established using standard criteria. Patients’ median age was 57 years range, Prior to treatment initiation all patients had splenomegaly, nine had anemia, five lymphocytosis, five neutropenia and six thrombocytopenia.

After treatment, all patients had a complete resolution of splenomegaly dsplenico with restoration of their blood counts. Among the complete responders seven patients had also a molecular remission. The median time to clinical response was 3 weeks range, Rituximab maintenance was given to 12 patients. Eleven of them had no evidence of disease progression after a median follow-up time of Median follow-up time for the entire series was No deaths were recorded during the follow-up period.

Therapy was well tolerated. The present study demonstrates that rituximab is an effective treatment lindoma SMZL and could be considered as a substitute or alternative to splenectomy.

Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Maria alle Scotte, and University of Siena, Italy.

This case demonstrates that rituximab monotherapy might also be a valid therapeutic approach in marginal zone lymphoma and autoimmune hemolytic anemia after failure of first-line treatment. Maintenance matginal, although expensive, could be useful to improve event-free survival in patients with unfavorable clinical behavior.

Rituximab monotherapy for splenic marginal zone lymphoma. Median response duration was 21 months range 4 to 37 months.

Two patients who relapsed at 21 and 23 months responded to retreatment. Rituximab should be considered in patients who are poor candidates for splenectomy. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Splenic MZL, which expresses the CD20 antigen on tumor cell surfaces, is a disease entity candidate to treatment with anti-CD20 monoclonal antibodies.

The immunochemotherapy regimen was matginal tolerated and all patients exhibited complete remission. To our knowledge, this is the first report of splenic MZL showing response to a combination of rituximab with chemotherapy.

How we decide when a neonate needs a transfusion. References of trials included in systematic review Reference 2 in.

Para el 20 de febrero – Haverford Township School District.